Ep. 381 - FIH urgency in the U.S. Plus: federated learning, biotech IPOs
From BioCentury This Week · · 31 min
This plays from the publisher's own server. We do not host a copy.
Description
Pressure is on FDA, policymakers and academic centers in the U.S. to respond to challenges from China, Australia, and beyond to run first in human trials (https://www.biocentury.com/article/660354) faster and more efficiently. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss how stakeholders in the U.S. are responding to the challenge. The analysts also discuss the next frontiers of federated learning in drug discovery and the latest crop of biotech IPOs (https://www.biocentury.com/article/660407) on NASDAQ, which raised over $1.2B in strong IPO run last week.
View full story: https://www.biocentury.com/article/660433
#ClinicalTrials #BiopharmaPolicy #DrugDevelopment #BiotechIPO #FederatedLearning
00:00- Introduction 01:15 - Academic Centers 10:42 - Policy Picture 15:48 - Grand Rounds Europe Highlights 18:01 - Federated Learning 28:15 - NASDAQ IPOs
To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.
Reach us by sending a text (https://www.buzzsprout.com/1035190/fan_mail/new)